 AVROBIO, Inc. Nasdaq: AVRO, a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the first patient has been dosed in the companys GuardOne clinical trial, a Phase 12 investigational study evaluating AVR-RD-02 for Gaucher disease type 1. The company also announced that the second patient has been dosed in the ongoing investigator-sponsored Phase 12 clinical trial of AVR-RD-04 for cystinosis. 